Depletion of dendritic cells enhances susceptibility to cell-free infection of human T cell leukemia virus type 1 in CD11c-diphtheria toxin receptor transgenic mice.
Human T cell leukemia virus type 1 (HTLV-1) is associated with two immunologically distinct diseases: HTLV-1-associated myelopathy/tropical spastic paraparesis and adult T cell leukemia. The genesis of these diseases is believed to be associated with the route (mucosa versus blood) and mode (cell-free versus cell-associated) of primary infection as well as the modulation of dendritic cell (DC) functions. To explore the role of DCs during early HTLV-1 infection in vivo, we used a chimeric HTLV-1 with a replaced envelope gene from Moloney murine leukemia virus to allow HTLV-1 to fuse with murine cells, which are generally not susceptible to infection with human retroviruses. We also used a CD11c-diphtheria toxin receptor transgenic mouse model system that permits conditional transient depletion of CD11c(+) DCs. We infected these transgenic mice with HTLV-1 using both cell-free and cell-associated infection routes in the absence and presence of DCs. The ablation of DCs led to an enhanced susceptibility to infection with cell-free but not cell-associated HTLV-1 in both CD4 and non-CD4 fractions, as measured by the proviral load. Infection with cell-free virus in the absence of DCs was also found to have increased levels of Tax mRNA in the non-CD4 fraction. Moreover, depletion of DCs significantly dampened the cellular immune response (IFN-gamma(+)CD8(+) T cells) against both cell-free and cell-associated virus. These results uniquely differentiate the involvement of DCs in early cell-free versus late cell-associated infection of HTLV-1 and highlight a significant aspect of viral immunopathogenesis related to the progression of adult T cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis after the initial infection.
Rahman
Saifur
S
Drexel Institute for Biotechnology and Virology Research, Drexel University College of Medicine, Philadelphia, PA 19127, USA.
Manuel
Sharrón L
SL
Khan
Zafar K
ZK
Wigdahl
Brian
B
Acheampong
Edward
E
Tangy
Frederic
F
Jain
Pooja
P
D000818:Animals; D039521:CD11c Antigen / Q000235:genetics*; D016923:Cell Death / Q000235:genetics / Q000276:immunology; D002460:Cell Line; D002474:Cell-Free System / Q000276:immunology / Q000473:pathology / Q000821:virology; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology; D004167:Diphtheria Toxin / Q000235:genetics / Q000378:metabolism; D004198:Disease Susceptibility / Q000276:immunology / Q000821:virology; D066257:Heparin-binding EGF-like Growth Factor; D015368:Human T-lymphotropic virus 1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics*; D007937:Leukapheresis / Q000379:methods; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D015493:Paraparesis, Tropical Spastic / Q000276:immunology* / Q000378:metabolism / Q000821:virology
D039521:CD11c Antigen; D004167:Diphtheria Toxin; C587883:HBEGF protein, human; C587884:Hbegf protein, mouse; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins
Ann Neurol. 1995 Feb;37(2):167-75
7847858
Blood. 1977 Sep;50(3):481-92
301762
Adv Exp Med Biol. 1993;329:545-9
8379424
AIDS Res Hum Retroviruses. 1992 Sep;8(9):1699-706
1457215
Clin Exp Immunol. 1993 Oct;94(1):32-7
8403513
J Virol. 1995 Jul;69(7):4149-57
7769674
Nat Med. 2008 Apr;14(4):429-36
18376405
Cancer Sci. 2007 Jun;98(6):772-8
17388788
Leukemia. 1997 Apr;11 Suppl 3:260-2
9209359
Science. 2003 May 23;300(5623):1295-7
12730499
Lancet. 1986 May 3;1(8488):1031-2
2871307
J Neuropathol Exp Neurol. 1991 Mar;50(2):97-107
1707091
Science. 2003 Mar 14;299(5613):1713-6
12589003
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Feb 1;17(2):167-70
9473019
J Exp Med. 2004 Jan 19;199(2):283-93
14734528
J Acquir Immune Defic Syndr (1988). 1990;3(11):1096-101
2213510
Immunity. 2002 Aug;17(2):211-20
12196292
Immunol Cell Biol. 2007 Jun;85(4):280-6
17372609
J Infect Dis. 2005 Jan 15;191(2):255-63
15609236
Ann Neurol. 1990 Jul;28(1):50-6
2375633
J Neuropathol Exp Neurol. 1989 Nov;48(6):610-9
2677251
Eur J Immunol. 2003 Oct;33(10):2736-43
14515257
J Neurovirol. 2004 Dec;10(6):358-71
15765807
Virology. 1996 Apr 1;218(1):279-84
8615036
Scand J Immunol. 2001 Dec;54(6):574-81
11902332
J Virol. 2006 Apr;80(8):3985-93
16571815
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3760-5
15728729
Blood. 2001 Sep 15;98(6):1858-61
11535522
J Leukoc Biol. 2007 Jul;82(1):44-56
17442856
J Virol. 2002 Aug;76(15):7883-9
12097602
Nat Rev Cancer. 2007 Apr;7(4):270-80
17384582
Trends Immunol. 2007 Dec;28(12):525-31
17964853
Lancet. 1985 Aug 24;2(8452):407-10
2863442
Acta Neuropathol. 1999 Feb;97(2):107-12
9928820
J Virol. 1995 May;69(5):2863-8
7707509
J Virol. 1999 Jun;73(6):4575-81
10233916
J Neurovirol. 2006 Feb;12(1):47-59
16595374
J Virol. 1998 May;72(5):3952-7
9557681
J Virol. 2009 Nov;83(21):10908-21
19692463
Virology. 2000 Aug 15;274(1):140-8
10936095
Hokkaido Igaku Zasshi. 1987 Jan;62(1):74-81
2880789
J Virol Methods. 2007 May;141(2):125-32
17204339
Blood. 1995 Aug 15;86(4):1444-52
7632951
Int J Cancer. 1989 Feb 15;43(2):250-3
2917802
Oncogene. 2005 Sep 5;24(39):6058-68
16155612
Blood. 2002 Jan 1;99(1):88-94
11756157
Br J Haematol. 2004 Jun;125(5):568-75
15147371
J Immunol. 2005 Apr 1;174(7):3920-4
15778347
J Immunol. 1995 Jun 1;154(11):5684-93
7751620
Immunity. 2000 Nov;13(5):657-64
11114378
Int J Cancer. 1983 Sep 15;32(3):321-8
6604033
Methods. 2001 Dec;25(4):402-8
11846609
J Virol. 1999 Jul;73(7):6031-40
10364355
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11784-8
1465399
Biomed Pharmacother. 2007 May;61(4):201-8
17391906
Science. 1988 Dec 16;242(4885):1557-9
3201246
J Leukoc Biol. 2009 Nov;86(5):1205-16
19656902
J Virol. 1990 Nov;64(11):5682-7
1976827
AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1737-40
11080819
J Cell Physiol. 2002 Feb;190(2):133-59
11807819
Nature. 1990 Nov 15;348(6298):245-8
2146511
Jpn J Cancer Res. 1999 Jan;90(1):48-54
10076564